HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.
Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3631219?pdf=render |
id |
doaj-ccc75852edbd4af88b50cfb78610698c |
---|---|
record_format |
Article |
spelling |
doaj-ccc75852edbd4af88b50cfb78610698c2020-11-25T01:20:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6156510.1371/journal.pone.0061565HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.Wen-Yee ChaySung-Hock ChewWhee-Sze OngInny BusmanisXinyun LiSharyl ThungLynette NgoSheow-Lei LimYong-Kuei LimYin-Nin ChiaElisa KohCindy PangLay-Tin SohJin WangTew-Hong HoSun-Kuie TaySoo-Kim Lim-TanKiat-Hon LimJohn Whay-Kuang ChiaLiang-Kee GohMucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers.http://europepmc.org/articles/PMC3631219?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wen-Yee Chay Sung-Hock Chew Whee-Sze Ong Inny Busmanis Xinyun Li Sharyl Thung Lynette Ngo Sheow-Lei Lim Yong-Kuei Lim Yin-Nin Chia Elisa Koh Cindy Pang Lay-Tin Soh Jin Wang Tew-Hong Ho Sun-Kuie Tay Soo-Kim Lim-Tan Kiat-Hon Lim John Whay-Kuang Chia Liang-Kee Goh |
spellingShingle |
Wen-Yee Chay Sung-Hock Chew Whee-Sze Ong Inny Busmanis Xinyun Li Sharyl Thung Lynette Ngo Sheow-Lei Lim Yong-Kuei Lim Yin-Nin Chia Elisa Koh Cindy Pang Lay-Tin Soh Jin Wang Tew-Hong Ho Sun-Kuie Tay Soo-Kim Lim-Tan Kiat-Hon Lim John Whay-Kuang Chia Liang-Kee Goh HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS ONE |
author_facet |
Wen-Yee Chay Sung-Hock Chew Whee-Sze Ong Inny Busmanis Xinyun Li Sharyl Thung Lynette Ngo Sheow-Lei Lim Yong-Kuei Lim Yin-Nin Chia Elisa Koh Cindy Pang Lay-Tin Soh Jin Wang Tew-Hong Ho Sun-Kuie Tay Soo-Kim Lim-Tan Kiat-Hon Lim John Whay-Kuang Chia Liang-Kee Goh |
author_sort |
Wen-Yee Chay |
title |
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. |
title_short |
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. |
title_full |
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. |
title_fullStr |
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. |
title_full_unstemmed |
HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. |
title_sort |
her2 amplification and clinicopathological characteristics in a large asian cohort of rare mucinous ovarian cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Mucinous epithelial ovarian cancer has a poor prognosis in the advanced stages and responds poorly to conventional chemotherapy. We aim to elucidate the clinicopathological factors and incidence of HER2 expression of this cancer in a large Asian retrospective cohort from Singapore. Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts. Most were Chinese (71%), followed by Malays (16%), others (9.0%), and Indians (5%). 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent. Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. HER2 positivity appeared to be lower among Chinese and higher among Malays patients (p = 0.052). With the current standard of care, there was no discernible impact of HER2 status on overall survival. (HR = 1.79; 95% CI, 0.66-4.85; p = 0.249). On the other hand, positive family history of cancer, presence of lymphovascular invasion, and ovarian surface involvements were significantly associated with inferior overall survival on univariate and continued to be statistically significant after adjustment for stage. While these clinical factors identify high risk patients, it is promising that the finding of a high incidence of HER2 in our Asian population may allow development of a HER2 targeted therapy to improve the management of mucinous ovarian cancers. |
url |
http://europepmc.org/articles/PMC3631219?pdf=render |
work_keys_str_mv |
AT wenyeechay her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT sunghockchew her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT wheeszeong her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT innybusmanis her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT xinyunli her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT sharylthung her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT lynettengo her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT sheowleilim her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT yongkueilim her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT yinninchia her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT elisakoh her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT cindypang her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT laytinsoh her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT jinwang her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT tewhongho her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT sunkuietay her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT sookimlimtan her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT kiathonlim her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT johnwhaykuangchia her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer AT liangkeegoh her2amplificationandclinicopathologicalcharacteristicsinalargeasiancohortofraremucinousovariancancer |
_version_ |
1725135993373196288 |